Navigation Links
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Date:3/23/2009

cancer in this country in 2008 and 15,520 deaths because of the disease. In Europe, it is estimated that there are 61,000 cases of ovarian cancer each year.

About Morphotek

Morphotek, Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machine
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
9. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...dontics, Ltd. (Tonawanda, N.Y.) offers DentaSOAK&r... to kill more than 99% of infection-causing bacter... Tonawanda, NY (PRWEB) November 23, 2009... found that mouthguards used regularly are highly ... staph to strep to pneumococci. The results of the...
(Date:11/22/2009)...viewed by many young children in child care settin...od screen time, with those in home-based settings ...in center-based daycares. This study is the first...more than 20 years. The study looked at televisio...nd was guided by lead researcher Dimitri A. Christ...
(Date:11/22/2009)...hen people have malaria, they are infected with Pl...saliva of a mosquito, infect cells in the liver, a...d cells, the parasites replicate and also begin to... change the physical nature of the cells in the bl...blood cells are stiffer and stickier than normal o...
(Date:11/22/2009)...ontrol, expert says , , SUNDAY, Nov. 22 ...l be faced with a seemingly endless buffet of food...eat too much, others deny themselves any holiday t... overindulgence and deprivation, according to Juli...t Brigham and Women,s Hospital in Boston. She offe...
(Date:11/22/2009)...SNewswire/ -- Congressman Chaka Fattah (D-PA) issu...Senate,s vote tonight to proceed to debate on Affo...len Specter and Bob Casey deserve the thanks of Ph...and-up, critical votes in the Senate tonight advan...Care Reform legislation to full debate. The Presid...
Breaking Medicine News(10 mins):Health News:DentaSOAK Dental Cleaner Reduces Infection Risk Linked to Mouthguards 2Health News:Daycare may double TV time for young children, study finds 2Health News:Daycare may double TV time for young children, study finds 3Health News:Daycare may double TV time for young children, study finds 4Health News:Measuring and modeling blood flow in malaria 2Health News:Go Healthy, Not Hungry for Holiday Eating 2
...established fact that any genetic alterations in e...east cancer. The BRCA1 gene, has been known to pla...ogen in cells present in the breast. Researchers f... The results of the present study can be fo...
...t the University of Manchester have evolved a meth...echniques employed to detect chemical warfare agen...ing a sensor employed to check out explosives at t...y" molecules emanating from the breath of a patien...
...istration of Quinolone antibiotics for eardrum per...reating the disease than the use of systemic antib...e, International Health Research Group in the Live...iotics for treating chronic discharge from ears. ...
...y seen that the usage of aspirin to prevent heart ...searchers at the University of Pittsburgh Graduate...ed the study and published in the American Journal...rope measured regular use of aspirin among 2,163 A...
...h conducted by Derek Griffiths, Ph.D., professor o...ool of Medicine, said that poor bladder// control ...l cortex of the brain. He reported his findin...he brain activity of 6 normal people and 6 people ...
...n an increase in the number of breast cancer cases...o have been diagnosed with the ductal carcinoma// ... is engaged in finding out which of the hormone th...CIS is considered a pre-cancerous condition, which...
Other Medicine News:Health News:Scientists Unravel Link Between HRT And Breast Cancer Gene, BRCA1 2Health News:Sensor Can Detect "Unhealthy" Molecules In Breath 2
(Date:11/20/2009)...Y, N.C., Nov. 20 Corners...ty pharmaceutical company focused on acquiring, de...primarily for the respiratory and related markets,...ter from the Food and Drug Administration ("FDA") ...enylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) a...
(Date:11/20/2009)...WOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- L...sults for the fiscal fourth quarter and full year ..., The company will host a conference call for i.... Eastern Time. Investors may access the live call... and Canada), or 480-629-9835 (international calle...
(Date:11/20/2009)...RRISBURG, Pa., Nov. 20 ...e H1N1 flu shots to members of priority groups tha..., A total of 18 clinics are being held statewide ...m. to 8 p.m. Hours on Saturday, Nov. 21, will be 8...ll operate from 2 p.m. to 8 p.m. ,, Individual...
Breaking Medicine Technology:Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2Blue Cross Blue Shield of Michigan Releases Letter Sent to Congressmen John Dingell and Sander Levin 55052 1Blue Cross Blue Shield of Michigan Releases Letter Sent to Congressmen John Dingell and Sander Levin 55052 2Blue Cross Blue Shield of Michigan Releases Letter Sent to Congressmen John Dingell and Sander Levin 55052 3Blue Cross Blue Shield of Michigan Releases Letter Sent to Congressmen John Dingell and Sander Levin 55052 4Gene Linked to Inherited Kidney Disease Found 55049 1Swine Flu Vaccine Seems Safe in Early Trials 55046 1Swine Flu Vaccine Seems Safe in Early Trials 55046 2Swine Flu Vaccine Seems Safe in Early Trials 55046 3
...rnational Conference on Antiviral,Research, SAN DI...RX,Pharmaceuticals, Inc. , a biopharmaceutical res...lizing proprietary product,candidates for the trea... today that it presented results demonstrating syn...a (bird flu) viruses when,the Company,s broad-spec...
...--May 4, 2007 - New data have,demonstrated that re...ts treated with COPAXONE(R) (glatiramer acetate in...toxantrone experienced a,90 percent reduction in m...activity compared to their baseline. These benefit...hout the 24-month study,period. These long-term da...
Other Medicine Technology:ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 2ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7
Shutt® Small Joint Graspers
Acutrak Fusion Screw
...he SR™ Hand Implant System utilizes the same...acements. The SR™ Hand Implant System provi...ostheses including minimal bone resection, surface...ous articular surfaces, retention and/or repositio...
...y providing a single system that enables three pro... 3 Anterior Cervical Plate System the smart choice...3 System simplifies anterior cervical spinal fusio...nd unconstrained procedures through innovative, in...
Medicine Products: